High-affinity binding of southern African HIV type 1 subtype C envelope protein, gp120, to the CCR5 coreceptor

AIDS Research and Human Retroviruses

Volumn 24, Issue 12, 2008, Pages 1527-1536

  Fromme, Bernhard J ^a,c   Coetsee, Marla ^a   Van Der Watt, Pauline ^a,d   Chan, Mei Chi ^a   Sperling, Karin M ^a,e   Katz, Arieh A ^a   Flanagan, Colleen A ^a,b,f  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c Centurion Business Park   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e PAUL EHRLICH INSTITUT   (Germany)

^f UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SOUTH AFRICA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AFRICA, SOUTHERN; AMINO ACID SUBSTITUTION; ANTIGENS, CD4; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; PROTEIN BINDING; RECEPTORS, CCR5;

EID: 58149141565     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0105     Document Type: Article

References (72)

1. Berger EA, Murphy PM, and Farber JM: Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
2. Moore JP, Kitchen SG, Pugach P, and Zack JA: The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004;20:111-126.
3. Aasa-Chapman MM, Aubin K, Williams I, and McKnight A: Primary CCR5 only using HIV-1 isolates does not accurately represent the in vivo replicating quasi-species. Virology 2006;351:489-496.
4. Arenzana-Seisdedos F and Parmentier M: Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands. Semin Immunol 2006;18:387-403.
5. Veazey RS, Klasse PJ, Schader SM, et al.: Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005;438:99-102.
6. Moore JP and Stevenson M: New targets for inhibitors of HIV-1 replication. Nat Rev Mol Cell Biol 2000;1:40-49.
7. Palani A and Tagat JR: Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists. J Med Chem 2006;49:2851-2857.
8. Gulick RM, Su Z, Flexner C, et al.: Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J Infect Dis 2007;196:304-312.
9. Fatkenheuer G, Pozniak AL, Johnson MA, et al.: Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005;11:1170-1172.
10. Essex M: State of the HIV pandemic [editorial]. J Hum Virol 1998;1:427-429.
11. Perrin L, Kaiser L, and Yerly S: Travel and the spread of HIV-1 genetic variants. Lancet Infect Dis 2003;3:22-27.
12. Soares EA, Martinez AM, Souza TM, et al.: HIV-1 subtype C dissemination in southern Brazil. AIDS 2005;19(Suppl. 4):S81-86.
13. Nkolola JP and Essex M: Progress towards an HIV-1 subtype C vaccine. Vaccine 2006;24:391-401.
14. Tatt ID, Barlow KL, Clewley JP, Gill ON, and Parry JV: Surveillance of HIV-1 subtypes among heterosexuals in England and Wales, 1997-2000. J Acquir Immune Defic Syndr 2004;36:1092-1099.
15. Ball SC, Abraha A, Collins KR, et al.: Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol 2003;77:1021-1038.
16. Rainwater S, DeVange S, Sagar M, et al.: No evidence for rapid subtype C spread within an epidemic in which multiple subtypes and intersubtype recombinants circulate. AIDS Res Hum Retroviruses 2005;21:1060-1065.
17. Novitsky V, Smith UR, Gilbert P, et al.: Human immunodeficiency virus type 1 subtype C molecular phylogeny: Consensus sequence for an AIDS vaccine design? J Virol 2002;76:5435-5451.
18. Sanabani S, Neto WK, de Sa Filho DJ, et al.: Full-length genome analysis of human immunodeficiency virus type 1 subtype C in Brazil. AIDS Res Hum Retroviruses 2006;22:171-176.
19. Novitsky VA, Montano MA, McLane MF, et al.: Molecular cloning and phylogenetic analysis of human immunodeficiency virus type 1 subtype C: A set of 23 full-length clones from Botswana. J Virol 1999;73:4427-4432.
20. Rodenburg CM, Li Y, Trask SA, et al.: Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res Hum Retroviruses 2001;17:161-168.
21. Papathanasopoulos MA, Patience T, Meyers TM, McCutchan FE, and Morris L: Full-length genome characterization of HIV type 1 subtype C isolates from two slow-progressing perinatally infected siblings in South Africa. AIDS Res Hum Retroviruses 2003;19:1033-1037.
22. Kothe DL, Li Y, Decker JM, et al.: Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 2006;352:438-449.
23. Gray ES, Meyers T, Gray G, Montefiori DC, and Morris L: Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med 2006;3:e255.
24. Li M, Salazar-Gonzalez JF, Derdeyn CA, et al.: Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 2006;80:11776-11790.
25. Tscherning C, Alaeus A, Fredriksson R, et al.: Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 1998;241:181-188.
26. Cilliers T, Nhlapo J, Coetzer M, et al.: The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol 2003;77:4449-4456.
27. Coetzer M, Cilliers T, Ping LH, Swanstrom R, and Morris L: Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology 2006;356:95-105.
28. Salemi M, de Oliveira T, Soares MA, et al.: Different epidemic potentials of the HIV-1B and C subtypes. J Mol Evol 2005;60:598-605.
29. Renjifo B, Gilbert P, Chaplin B, et al.: Emerging recombinant human immunodeficiency viruses: Uneven representation of the envelope V3 region. AIDS 1999;13:1613-1621.
30. McNearney T, Hornickova Z, Markham R, et al.: Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci USA 1992;89:10247-10251.
31. Ping LH, Nelson JA, Hoffman IF, et al.: Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: Underrepresentation of X4 variants. J Virol 1999;73:6271-6281.
32. Clerici M, Butto S, Lukwiya M, et al.: Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project. AIDS 2000;14:2083-2092.
33. Kwong PD, Wyatt R, Robinson J, et al.: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody [see comments]. Nature 1998;393:648-659.
34. Chen B, Vogan EM, Gong H, et al.: Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005;433:834-841.
35. Kwong PD: Human immunodeficiency virus: Refolding the envelope. Nature 2005;433:815-816.
36. Wyatt R and Sodroski J: The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 1998;280:1884-1888.
37. Decker JM, Bibollet-Ruche F, Wei X, et al.: Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005;201:1407-1419.
38. Edwards TG, Hoffman TL, Baribaud F, et al.: Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. J Virol 2001;75:5230-5239.
39. Gray ES, Moore PL, Choge IA, et al.: Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 2007;81:6187-6196.
40. van Harmelen J, Williamson C, Kim B, et al.: Characterization of full-length HIV type 1 subtype C sequences from South Africa. AIDS Res Hum Retroviruses 2001;17:1527-1531.
41. Williamson C, Morris L, Maughan MF, et al.: Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses 2003;19:133-144.
42. Van Harmelen JH, Van der Ryst E, Loubser AS, et al.: A predominantly HIV type 1 subtype C-restricted epidemic in South African urban populations. AIDS Res Hum Retroviruses 1999;15:395-398.
43. Ndung'u T, Renjifo B, Novitsky VA, et al.: Molecular cloning and biological characterization of full-length HIV-1 subtype C from Botswana. Virology 2000;278:390-399.
44. Maddon PJ, Littman DR, Godfrey M, et al.: The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: A new member of the immunoglobulin gene family. Cell 1985;42:93-104.
45. Andre S, Seed B, Eberle J, et al.: Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 1998;72:1497-1503.
46. Haas J, Park EC, and Seed B: Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996;6:315-324.
47. Jenkinson S, McCoy DC, Kerner SA, et al.: Development of a novel high-throughput surrogate assay to measure HIV envelope/CCR5/CD4-mediated viral/cell fusion using Bac-Mam baculovirus technology. J Biomol Screen 2003;8:463-470.
48. Millar RP, Davidson J, Flanagan C, and Wakefield I: Ligand binding and second-messenger assays for cloned Gq/G11-coupled neuropeptide receptors: The GnRH receptor. Methods Neurosci 1995;25:145-162.
49. Hoffman TL, LaBranche CC, Zhang W, et al.: Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc Natl Acad Sci USA 1999;96:6359-6364.
50. Earl PL, Broder CC, Long D, et al.: Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 1994;68:3015-3026.
51. Sattentau QJ and Moore JP: Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 1991;174:407-415.
52. Flanagan CA, Fromme BJ, Davidson JS, and Millar RP: A high affinity gonadotropin-releasing hormone (GnRH) tracer, radioiodinated at position 6, facilitates analysis of mutant GnRH receptors. Endocrinology 1998;139:4115-4119.
53. Wu L, Gerard NP, Wyatt R, et al.: CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996;384:179-183.
54. Trkola A, Dragic T, Arthos J, et al.: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 [see comments]. Nature 1996;384:184-187.
55. Farzan M, Mirzabekov T, Kolchinsky P, et al.: Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 1999;96:667-676.
56. Blanpain C, Doranz BJ, Vakili J, et al.: Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein. J Biol Chem 1999;274:34719-34727.
57. Motulsky H: Analyzing Data with Graphpad Prism. Version 3.0 Ed. GraphPad Software Inc, San Diego, CA, 1999.
58. Hulme EC: Receptor-Ligand Interactions. A Practical Approach, 1st ed. Oxford University Press, Oxford, UK, 1992.
59. Doranz BJ, Baik SS, and Doms RW: Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events. J Virol 1999;73:10346-10358.
60. Leonard CK, Spellman MW, Riddle L, et al.: Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990;265:10373-10382.
61. Lavillette D, Barbouche R, Yao Y, et al.: Significant redox insensitivity of the functions of the SARS-CoV spike glycoprotein: Comparison with HIV envelope. J Biol Chem 2006;281:9200-9204.
62. Ryser HJ, Levy EM, Mandel R, and DiSciullo GJ: Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction. Proc Natl Acad Sci USA 1994;91:4559-4563.
63. Tschachler E, Buchow H, Gallo RC, and Reitz MS Jr: Functional contribution of cysteine residues to the human immunodeficiency virus type 1 envelope. J Virol 1990;64:2250-2259.
64. Lekutis C, Olshevsky U, Furman C, Thali M, and Sodroski J: Contribution of disulfide bonds in the carboxyl terminus of the human immunodeficiency virus type I gp120 glycoprotein to CD4 binding. J Acquir Immune Defic Syndr 1992;5:78-81.
65. Jobes DV, Daoust M, Nguyen V, et al.: High incidence of unusual cysteine variants in gp120 envelope proteins from early HIV type 1 infections from a phase 3 vaccine efficacy trial. AIDS Res Hum Retroviruses 2006;22:1014-1021.
66. Hill CM, Deng H, Unutmaz D, et al.: Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. J Virol 1997;71:6296-6304.
67. Baik SS, Doms RW, and Doranz BJ: HIV and SIV gp120 binding does not predict coreceptor function. Virology 1999;259:267-273.
68. Marozsan AJ, Moore DM, Lobritz MA, et al.: Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J Virol 2005;79:7121-7134.
69. Olshevsky U, Helseth E, Furman C, et al.: Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol 1990;64:5701-5707.
70. Morrison HG, Kirchhoff F, and Desrosiers RC: Effects of mutations in constant regions 3 and 4 of envelope of simian immunodeficiency virus. Virology 1995;210:448-455.
71. Deng H, Liu R, Ellmeier W, et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-666.
72. Morgenstern JP and Land H: Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990;18:3587-3596.